Trifarotene Plus Skin Care Beneficial for Acne Vulgaris
By Elana Gotkine HealthDay Reporter
WEDNESDAY, May 8, 2024 -- Trifarotene plus skin care is beneficial for patients with moderate acne vulgaris (AV) and acne-induced hyperpigmentation (AIH), according to a study published online April 29 in the International Journal of Dermatology.
Andrew Alexis, M.D., M.P.H., from Weill Cornell Medical College in New York City, and colleagues conducted a phase IV, double-blind, parallel-group study of patients aged 13 to 35 years with moderate AV and AIH who were treated with trifarotene or vehicle (63 and 60 patients, respectively), plus a skin care regimen of moisturizer, cleanser, and sunscreen for 24 weeks.
The researchers found that compared with vehicle, trifarotene 50 µg/g cream significantly improved the AIH overall disease severity score from baseline (−1.6 versus −1.1) at week 12, but at week 24, scores were comparable. At week 24, there was a better reduction in the post-AV hyperpigmentation index score with trifarotene (−18.9 versus −11.3 percent). At weeks 12 and 24, lesion count reductions were higher with trifarotene than vehicle, as were Investigator Global Assessment success rates. The skin care regimen contributed to less irritation, making adherence to treatment easier. Across all skin types, photography showed improvements in pigmentation and erythema. The vehicle group experienced more adverse events than the trifarotene group (30.2 versus 16.7 percent).
"This study shows that trifarotene cream has a favorable efficacy and safety profile for treating AV and AIH in subjects with all skin types, which likely will translate to overall improved outcomes for AV patients," the authors write.
Several authors disclosed ties to pharmaceutical companies, including Galderma, which manufactures trifarotene and funded the study.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Stigma Affects Quality of Life in Children With Chronic Skin Conditions
TUESDAY, April 30, 2024 -- Health care professionals should consider stigmatization and bullying in assessing the social and mental health of children and adolescents with chronic...
Review Explores Cutaneous Manifestations of Myelodysplastic Syndrome
FRIDAY, April 19, 2024 -- Cutaneous manifestations of myelodysplastic syndrome (MDS) are described in a perspective piece published in the April issue of Skin Health and...
Study Identifies Factors That Affect Antibiotic Prescribing for Acne
WEDNESDAY, April 10, 2024 -- Multiple salient factors affect long-term antibiotic prescribing practices for acne, according to a study published online April 3 in JAMA...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.